LPL Financial
CVKD icon

LPL Financial’s Cadrenal Therapeutics CVKD Stock Holding History

LPL Financial’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,000
Closed -$88.1K – 6026
2025
Q4 		$88.1K Sell
13,000
-1,200
-8% -$13.6K ﹤0.01% 5631
2025
Q3 		$196K Buy
+14,200
New +$176K ﹤0.01% 5352

Other funds holding CVKD

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
DWP
Destiny Wealth Partners Tavares, Florida $914M AUM 18.14% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

LPL Financial's CVKD Position: Q1 2026 in Review

LPL Financial sold out of Cadrenal Therapeutics (CVKD) in Q1 2026, closing a stake of 13,000 shares — an estimated $88.1K sold.

LPL Financial first reported a position in CVKD in Q3 2025 and held it in 2 quarters. The position peaked at $196K in Q3 2025. 20 funds tracked by Wall St. Rank hold CVKD as of Q1 2026.

  • LPL Financial reported no remaining Cadrenal Therapeutics position as of Q1 2026 after selling out during the quarter.
  • LPL Financial sold 13,000 Cadrenal Therapeutics shares in Q1 2026, an estimated $88.1K.
  • LPL Financial first reported a position in Cadrenal Therapeutics in Q3 2025 and held it in 2 quarters.
  • LPL Financial's Cadrenal Therapeutics position peaked at $196K in Q3 2025.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q1 2026.

Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.